Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR | Market Cap | 22.07B +20.3% |
| Revenue (ttm) | 3.06B +3.9% |
| Net Income | 323.90M +22.7% |
| EPS | 3.33 +22.9% |
| Shares Out | 97.30M |
| PE Ratio | 68.10 |
| Forward PE | 39.18 |
| Dividend | 0.69 (0.30%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 71,742 |
| Open | 223.00 |
| Previous Close | 223.40 |
| Day's Range | 222.00 - 226.80 |
| 52-Week Range | 150.00 - 229.80 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 250.00 (+10.23%) |
| Earnings Date | Oct 22, 2026 |
About Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog... [Read more]
Financial Performance
In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for DIM stock is "Buy." The 12-month stock price target is €250.00, which is an increase of 10.23% from the latest price.
News
Sartorius Stedim Biotech Earnings Call Transcript: Q3 2026
Nine-month sales and profitability improved, led by recurring consumables and a gradual equipment recovery. Sartorius Stedim Biotech raised cash generation, reduced leverage and maintained its 2026 outlook, while tariff headwinds and Q4 timing effects temper near-term growth.
Sartorius Stedim Biotech Earnings release: Q3 2026
Sartorius Stedim Biotech released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q3 2026
Sartorius Stedim Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Sartorius Stedim upgraded to Buy from Neutral at UBS
UBS upgraded Sartorius Stedim (SDMHF) to Buy from Neutral with a price target of EUR 260, up from EUR 220. The firm sees a positive setup into 2027 for the…
Sartorius Stedim Biotech Earnings Call Transcript: Q2 2026
Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables and equipment. Guidance for full-year revenue and margins is confirmed, despite tariff-related uncertainties and some delayed orders in advanced modalities.
Sartorius Stedim Biotech Earnings release: Q2 2026
Sartorius Stedim Biotech released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Quarterly report: Q2 2026
Sartorius Stedim Biotech has published its Q2 2026 quarterly earnings report on July 23, 2026.
Sartorius Stedim Biotech Slides: Q2 2026
Sartorius Stedim Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Sartorius Stedim price target lowered to EUR 230 from EUR 233 at HSBC
HSBC lowered the firm’s price target on Sartorius Stedim (SDMHF) to EUR 230 from EUR 233 and keeps a Buy rating on the shares. The firm says market expectations on…
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2026
Sales grew 7.5% in constant currencies in Q1 2026, with strong recurring business and resilient profitability. Full-year guidance is confirmed, expecting 5%-9% sales growth and EBITDA margin above 30%, while deleveraging and disciplined investment continue.
Sartorius Stedim Biotech Earnings release: Q1 2026
Sartorius Stedim Biotech released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q1 2026
Sartorius Stedim Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Sartorius Stedim upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst James Quigley upgraded Sartorius Stedim (SDMHF) to Buy from Neutral with a price target of EUR 214, down from EUR 235. The firm says the stock’s recent…
Sartorius Stedim Biotech Transcript: AGM 2026
The meeting confirmed strong 2025 financial growth, approved all resolutions, and outlined strategic priorities in innovation, operational efficiency, and sustainability. Dividend of €0.71 per share was proposed, and auditors issued unqualified opinions. All agenda items passed with high shareholder participation.
Sartorius Stedim Biotech Slides: FY 2026
Sartorius Stedim Biotech has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 24, 2026.
Sartorius Stedim upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux analyst Oliver Reinberg upgraded Sartorius Stedim (SDMHF) to Buy from Hold.
Sartorius Stedim Biotech Transcript: CMD 2026
Ambitious midterm targets include 8%-11% organic revenue growth and margin expansion, driven by innovation in single-use technologies, AI, and advanced therapies. Regional growth is led by the U.S. and Asia, with operational excellence and customer experience as key priorities.
Sartorius Stedim Biotech Press release: FY 2026
Sartorius Stedim Biotech issued a press release on March 17, 2026, disclosing material business information to investors.
Sartorius Stedim Biotech Slides: FY 2026
Sartorius Stedim Biotech has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Sartorius Stedim upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Sartorius Stedim (SDMHF) to Outperform from Sector Perform with a price target of EUR 210, down from EUR 240. The firm sees an attractive entry point following…
Sartorius Stedim Biotech Earnings Call Transcript: Q4 2025
Full-year results exceeded upgraded guidance, with strong recurring revenue growth and improved profitability. 2026 outlook anticipates 5%-9% sales growth and higher margins, supported by innovation, operational discipline, and a robust order book.
Sartorius Stedim Biotech Annual report: Q4 2025
Sartorius Stedim Biotech has published its Q4 2025 annual report on February 3, 2026.
Sartorius Stedim Biotech Earnings release: Q4 2025
Sartorius Stedim Biotech released its Q4 2025 earnings on February 3, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q4 2025
Sartorius Stedim Biotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Sartorius Stedim downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Sartorius Stedim (SDMHF) to Neutral from Buy with a EUR 246 price target The firm says the recovery in bioprocessing is now better reflected in the shares.